RLYB Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
-100.0%
212.0K
-4.5%
222.0K
+4.7%
212.0K
+0.0%
212.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
-100.0%
212.0K
-4.5%
222.0K
+4.7%
212.0K
+0.0%
212.0K
Operating Expenses
5.7M
-36.8%
8.9M
+34.8%
6.6M
-7.0%
7.1M
-30.5%
10.3M
R&D
758.0K
-73.6%
2.9M
-21.5%
3.7M
-11.8%
4.1M
-31.8%
6.1M
SG&A
4.9M
-19.4%
6.1M
+103.9%
3.0M
-0.5%
3.0M
-28.6%
4.2M
Operating Income
-5653000
+35.3%
-8733000
-36.2%
-6412000
+7.4%
-6925000
+31.1%
-10057000
EBITDA
-5651000
+35.3%
-8730000
-36.2%
-6409000
+7.0%
-6890000
+31.3%
-10031000
Net Income
43.7M
+627.5%
-8278000
-66.3%
-4978000
-131.1%
16.0M
+265.1%
-9703000
EPS (Basic)
$7.66
+624.7%
$-1.46
$2.88
+266.5%
$-1.73
EPS (Diluted)
$7.53
+615.8%
$-1.46
$2.88
+266.5%
$-1.73
Shares (Diluted)
5.8M
+1.9%
5.7M
5.6M
+0.5%
5.6M
Rallybio (RLYB) — Financials